Get the Daily Brief
Latest Biotech News
Recursion Pharmaceuticals Cuts Workforce by 20% Amid Pipeline Pruning and Funding Challenges
AI-driven drug developer Recursion Pharmaceuticals announced layoffs constituting approximately 20% of its workforce, equating to 160 positions, reflecting its pipeline streamlining and...
Cancer Drug Development: Antares Launches $177M Post-Scorpion Spinout Backed by Lilly
Antares Therapeutics, formed as a spinout from Scorpion Therapeutics after Lilly’s acquisition, has raised $177 million in a Series A round to continue advancing preclinical oncology drug...
FDA Clears Merck’s Pediatric RSV Antibody Amid U.S. Vaccine Advisory Turmoil
The FDA approved Merck's monoclonal antibody, Enflonsia (clesrovimab), for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants under 12 months....
Gene Therapy Funding Surge: SpliceBio’s $135M Series B and Dual AAV Gene Therapy Clinical Milestone
SpliceBio has secured $135 million in a Series B funding round co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Ventures and existing investors. The capital will...
FDA Places Clinical Hold on Gilead’s Long-Acting HIV Combo Trials
FDA halted multiple Gilead phase 1 and phase 2/3 trials for investigational HIV combo drugs following safety signals of immune cell count reductions, delaying critical research and raising...
Argenx Expands Autoimmune Drug Vyvgart Trials With Promising Results
Argenx announced promising data for its autoimmune drug Vyvgart in two new indications, expanding its therapeutic potential beyond current approvals. The positive results bolster Argenx's pipeline...
RFK Jr. ousts entire CDC vaccine advisory committee
HHS Secretary Robert F. Kennedy Jr. has removed all 17 members of the CDC’s Advisory Committee on Immunization Practices (ACIP), pledging to replace them with his own appointees. This...
FDA Places Clinical Hold on Gilead’s Long-Acting HIV Combo Trials
The FDA has imposed a clinical hold on five Gilead studies testing combinations of investigational long-acting HIV drugs GS-1720 and GS-4182 due to a safety signal involving lowered CD4 and...
Metsera Shows Promising Phase I Data for Long-Acting Amylin Analogue Against Obesity
Metsera reported encouraging Phase I results for its amylin analogue MET-233i, exhibiting dose-dependent weight loss and a pharmacokinetic profile supporting once-monthly dosing. This therapy may...
Merck’s Oral PCSK9 Inhibitor Shows Significant Cholesterol Reduction in Phase III
Merck’s once-monthly oral PCSK9 inhibitor enlicitide decanoate demonstrated robust and clinically meaningful reductions in LDL cholesterol levels across two phase III Coralreef studies in...
NIH Scientists Protest Research Politicization and Funding Cuts
Over 300 current and former NIH staff signed the Bethesda Declaration protesting politicization and drastic budget cuts under the Trump administration and NIH leadership. They highlight terminated...
Alamar Biosciences Partners Globally for Alzheimer’s Proteomic Biomarker Study
Alamar Biosciences, alongside the Alzheimer’s Disease Data Initiative and Gates Ventures, launched a large-scale international collaboration to generate a comprehensive plasma proteomic dataset...
AI Models Unveil Key Gene Combinations Driving Complex Diseases
Northwestern University biophysicists developed a generative AI model, TWAVE, to decipher gene sets underlying polygenic diseases like diabetes and cancer. By integrating limited gene expression...
Tufts Chemists Advance Next-Gen Multireceptor Weight Loss Drugs
Researchers at Tufts University have designed a novel drug candidate targeting four hormone receptors—including GLP-1, GIP, and glucagon—to improve efficacy and safety in obesity management. This...
Argenx Expands Autoimmune Drug Vyvgart Trials With Promising Results
Argenx announced encouraging preliminary data for its antibody drug Vyvgart in two additional autoimmune diseases beyond its approved indications. The company is testing Vyvgart in multiple...
Recursion Pharmaceuticals Lays Off 20% As Biotech Funding Pressures Mount
Recursion Pharmaceuticals is cutting approximately 20% of its workforce in response to pipeline pruning and challenging capital markets. After merging with AI drug discovery firm Exscientia,...
FDA Approves Merck’s Pediatric RSV Antibody Amid CDC Panel Shakeup
The FDA has approved Merck's Enflonsia (clesrovimab), a monoclonal antibody for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants under 12 months. This...
Recursion Cuts 20% Workforce Amid Funding Pressures
Recursion Pharmaceuticals announced a workforce reduction of approximately 20%, citing capital market challenges and pipeline restructuring. The layoffs signal financial pressures and strategic...
Insilico’s Nach01 Model Debuts on AWS for Drug Design
Insilico Medicine launched the Nach01 foundation AI model on AWS Marketplace, integrating multimodal data processing to enhance accuracy and scalability in molecular prediction and retrosynthesis,...
NIH Staff Rally Against Politicization and Grant Cuts
Over 300 NIH staff members have publicly protested drastic funding reductions and grant terminations under the current administration, highlighting risks to biomedical research integrity and...